Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NCT05645380)

🧪 Interventions in This Study

• Carboplatin (DRUG)
• Docetaxel (DRUG)
• Doxorubicin (DRUG)
• Cyclophosphamide (DRUG)
• Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

• The University of Kansas Cancer Center - Clinical Research Center — Fairway, Kansas
• The University of Kansas Cancer Center - Main Hospital — Kansas City, Kansas
• The University of Kansas Cancer Center - Westwood — Kansas City, Kansas
• The University of Kansas Cancer Center - Overland Park — Overland Park, Kansas
• The University of Kansas Cancer Center - North — Kansas City, Missouri
• The University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
• University of Kansas Cancer Center at North Kansas City Hospital — North Kansas City, Missouri

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Triple Negative Breast Cancer

• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Tucson, Arizona
• Comparison of the Breast Tumor Microenvironment — New York, New York
• Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer — Chicago, Illinois
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo — Mobile, Alabama
• Ribociclib and Bicalutamide in AR+ TNBC — Chicago, Illinois
• Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC — La Jolla, California

Explore by condition: All Triple Negative Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.